Balsalazide_disodium: profile and news

Salix Pharmaceuticals Reports 4Q2005 and FY2005 Results; 2005 ... Feb 24, 2006
COLAZAL(R) (balsalazide disodium) Capsules 750 mg, is an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. ... - Genetic Engineering News,

Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials ... Jan 11, 2006
COLAZAL (balsalazide disodium), formulated as an 1100 mg tablet, dosed three tablets twice daily, is being investigated in a multi-center, placebo-controlled ... - Business Wire (press release),

Salix Pharmaceuticals Acquires Patent-Protected, Liquid Peg Bowel ... Dec 7, 2005
Salix markets COLAZAL(R) (balsalazide disodium) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets (sodium phosphate monobasic ... - Genetic Engineering News,

Salix Pharmaceuticals Reports 3Q2005 Results Nov 8, 2005
Salix's first marketed product is COLAZAL(R) (balsalazide disodium) Capsules 750 mg, an anti-inflammatory drug approved for the treatment of mildly to ... - Business Wire (press release),

Salix Pharmaceuticals Completes Merger with InKine Pharmaceutical ... Oct 3, 2005
COLAZAL(R) (balsalazide disodium) Capsules 750 mg, is an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. ... - Business Wire (press release),

Salix Announces Publication of Study Results Suggesting ... Aug 25, 2005
In this double-blind, placebo-controlled, randomized trial, patients with prostate cancer were given three COLAZAL(R) (balsalazide disodium) Capsules 750 mg ... - Genetic Engineering News, <**results**>

Salix Pharmaceuticals to Acquire InKine Pharmaceutical; Strategic ... Jun 23, 2005
Salix's first marketed product is COLAZAL(R) (balsalazide disodium) Capsules 750 mg, an anti-inflammatory drug approved for the treatment of mildly to ... - Business Wire (press release),

Salix Pharmaceuticals Reports 1Q2005 Results; Total Product ... May 11, 2005
Salix's first marketed product is COLAZAL(R) (balsalazide disodium) Capsules 750 mg, an anti-inflammatory drug approved for the treatment of mildly to ... - Business Wire,

Salix Pharmaceuticals Reports 4Q2004 and FY2004 Results; Salix ... Feb 15, 2005
Salix's first marketed product is COLAZAL(R)(balsalazide disodium) Capsules 750 mg, an anti-inflammatory drug approved for the treatment of mildly to ... - Business Wire (press release),

Other information

Indication
For the treatment of mildly to moderately active ulcerative colitis

Pharmacology
Balsalazide is a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and 4-aminobenzoyl-(beta)-alanine.

Mechanism Of Action
The mechanism of action of 5-aminosalicylic acid is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon.

Drug Category
Anti-ulcer Agents; ATC:A07EC04

Brand Names/Synonyms
BALSALAZIDE; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Carbadox; Colazal

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Interactions for Balsalazide:

No drug interaction studies have been conducted for COLAZAL ô, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.

Chemical IUPAC Name
5-[4-(2-carboxyethylcarbamoyl)phenyl]azo-2-hydroxy-benzoicacid

Chemical Formula
C17H15N3O6

Half Life
half-life could not be determined

Drug Type
Approved Drug

# Accession No
APRD00141

CAS Registry Number
80573-04-2